Unicycive Therapeutics Stock Market Value
| UNCY Stock | USD 0.68 0 0.29% |
| Symbol | Unicycive |
Unicycive Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Unicycive Therapeutics. If investors know Unicycive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Unicycive Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Return On Assets (0.53) | Return On Equity (1.22) |
The market value of Unicycive Therapeutics is measured differently than its book value, which is the value of Unicycive that is recorded on the company's balance sheet. Investors also form their own opinion of Unicycive Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Unicycive Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Unicycive Therapeutics' market value can be influenced by many factors that don't directly affect Unicycive Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Unicycive Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Unicycive Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Unicycive Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Unicycive Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Unicycive Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Unicycive Therapeutics.
| 12/09/2022 |
| 11/28/2024 |
If you would invest 0.00 in Unicycive Therapeutics on December 9, 2022 and sell it all today you would earn a total of 0.00 from holding Unicycive Therapeutics or generate 0.0% return on investment in Unicycive Therapeutics over 720 days. Unicycive Therapeutics is related to or competes with Transcode Therapeutics, and Cardio Diagnostics. Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the ... More
Unicycive Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Unicycive Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Unicycive Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.91 | |||
| Information Ratio | 0.1334 | |||
| Maximum Drawdown | 29.22 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 9.76 |
Unicycive Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Unicycive Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Unicycive Therapeutics' standard deviation. In reality, there are many statistical measures that can use Unicycive Therapeutics historical prices to predict the future Unicycive Therapeutics' volatility.| Risk Adjusted Performance | 0.129 | |||
| Jensen Alpha | 0.6232 | |||
| Total Risk Alpha | (0.01) | |||
| Sortino Ratio | 0.1218 | |||
| Treynor Ratio | 0.4667 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Unicycive Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Unicycive Therapeutics Backtested Returns
Unicycive Therapeutics is dangerous given 3 months investment horizon. Unicycive Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.22, which indicates the firm had a 0.22% return per unit of risk over the last 3 months. We were able to break down twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.26% are justified by taking the suggested risk. Use Unicycive Therapeutics Coefficient Of Variation of 634.78, semi deviation of 4.32, and Risk Adjusted Performance of 0.129 to evaluate company specific risk that cannot be diversified away. Unicycive Therapeutics holds a performance score of 17 on a scale of zero to a hundred. The entity has a beta of 1.8, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Unicycive Therapeutics will likely underperform. Use Unicycive Therapeutics maximum drawdown, as well as the relationship between the skewness and price action indicator , to analyze future returns on Unicycive Therapeutics.
Auto-correlation | 0.54 |
Modest predictability
Unicycive Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Unicycive Therapeutics time series from 9th of December 2022 to 4th of December 2023 and 4th of December 2023 to 28th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Unicycive Therapeutics price movement. The serial correlation of 0.54 indicates that about 54.0% of current Unicycive Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.54 | |
| Spearman Rank Test | -0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 0.15 |
Unicycive Therapeutics lagged returns against current returns
Autocorrelation, which is Unicycive Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Unicycive Therapeutics' stock expected returns. We can calculate the autocorrelation of Unicycive Therapeutics returns to help us make a trade decision. For example, suppose you find that Unicycive Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Unicycive Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Unicycive Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Unicycive Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Unicycive Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Unicycive Therapeutics Lagged Returns
When evaluating Unicycive Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Unicycive Therapeutics stock have on its future price. Unicycive Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Unicycive Therapeutics autocorrelation shows the relationship between Unicycive Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Unicycive Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.